Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Retinopathy Of Prematurity - Overview
Retinopathy Of Prematurity - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Retinopathy Of Prematurity - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Retinopathy Of Prematurity - Companies Involved in Therapeutics Development
Advanced Imaging Projects Inc
Anida Pharma Inc
AntlerA Therapeutics Inc
Ayuvis Research Inc
D. Western Therapeutics Institute Inc
Drive Therapeutics LLC
Everglades Biopharma LLC
Insmed Inc
Kowa Co Ltd
Novelty Nobility Inc
Orphanix GmbH
Pamdeca LLC
Recordati Rare Diseases Inc
Regeneron Pharmaceuticals Inc
Sigblok Inc
Worphmed Srl
Retinopathy Of Prematurity - Drug Profiles
aflibercept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVR-123 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
D-2P014 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Diabetic Retinopathy and Retinopathy of Prematurity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Retinopathy of Prematurity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mecasermin rinfabate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
melatonin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibodies to Inhibit SCG3 for Oncology, Ophthalmology and Diabetic Complications - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibody to Agonize Frizzled receptor 4 and LRP5 for Diabetic Retinopathy and Retinopathy of Prematurity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neuroprotectin D1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NN-2901 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PMD-336 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Propranolol hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ripasudil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Retinopathy of Prematurity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit TREM-1 for Oncology, Sepsis, Rheumatoid Arthritis, Retinopathy Of Prematurity and Hemorrhagic Shock - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vitamin A palmitate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Retinopathy Of Prematurity - Dormant Projects
Retinopathy Of Prematurity - Product Development Milestones
Featured News & Press Releases
Mar 11, 2019: Bascom Palmer’s Dr. Wei Li awarded $9.12 million NEI grant
Jun 30, 2016: Shire Announces Top-Line Results for Phase 2 Trial of SHP607 in Extremely Premature Infants
Jan 21, 2009: Insmed And Premacure Announce European Orphan Desigtion For IPLEX In Retinopathy Of Prematurity In Infants
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Retinopathy Of Prematurity, 2021
Number of Products under Development by Companies, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development for Retinopathy Of Prematurity, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Retinopathy Of Prematurity - Pipeline by Advanced Imaging Projects Inc, 2021
Retinopathy Of Prematurity - Pipeline by Anida Pharma Inc, 2021
Retinopathy Of Prematurity - Pipeline by AntlerA Therapeutics Inc, 2021
Retinopathy Of Prematurity - Pipeline by Ayuvis Research Inc, 2021
Retinopathy Of Prematurity - Pipeline by D. Western Therapeutics Institute Inc, 2021
Retinopathy Of Prematurity - Pipeline by Drive Therapeutics LLC, 2021
Retinopathy Of Prematurity - Pipeline by Everglades Biopharma LLC, 2021
Retinopathy Of Prematurity - Pipeline by Insmed Inc, 2021
Retinopathy Of Prematurity - Pipeline by Kowa Co Ltd, 2021
Retinopathy Of Prematurity - Pipeline by Novelty Nobility Inc, 2021
Retinopathy Of Prematurity - Pipeline by Orphanix GmbH, 2021
Retinopathy Of Prematurity - Pipeline by Pamdeca LLC, 2021
Retinopathy Of Prematurity - Pipeline by Recordati Rare Diseases Inc, 2021
Retinopathy Of Prematurity - Pipeline by Regeneron Pharmaceuticals Inc, 2021
Retinopathy Of Prematurity - Pipeline by Signablok Inc, 2021
Retinopathy Of Prematurity - Pipeline by Worphmed Srl, 2021
Retinopathy Of Prematurity - Dormant Projects, 2021